Please login to the form below

Not currently logged in
Email:
Password:

Newron Pharmaceuticals

This page shows the latest Newron Pharmaceuticals news and features for those working in and with pharma, biotech and healthcare.

FDA approves Newron's Parkinson's disease drug Xadago

FDA approves Newron's Parkinson's disease drug Xadago

FDA approves Newron's Parkinson's disease drug Xadago. Becomes first new treatment licensed for the condition in over a decade. ... Newron Pharmaceuticals’Xadago (safinamide) was approved as an add-on treatment for patients already on

Latest news

  • Newron back on track for Xadago approval in US Newron back on track for Xadago approval in US

    Newron back on track for Xadago approval in US. Italian firm is not required to conduct additional trials for its Parkinson’ s disease drug. ... Newron Pharma will not have to conduct any additional clinical trials for its Parkinson's disease drug

  • Alzheimer's disease pipeline takes multiple hits Alzheimer's disease pipeline takes multiple hits

    modulator EVP 0962 (EnVivo Pharmaceuticals); the metal protein-attenuating compound called PBT 2 (Prana Biotechnology); and ELND 005 (Speranza Therapeutics). ... Another agent HF 0220 (Newron Pharmaceuticals), an oral epiandrosterone derivative thought

  • Pharma deals for June 2012 Pharma deals for June 2012

    Elan. Newron Pharmaceuticals shows further signs of moving on from Merck Serono's decision in 2011 to return the rights to safinamide, which in turn prompted Biotie to abandon its planned ... 300. Savira pharmaceuticals GmbH / Roche. Collaboration and

  • Pharma deals for April 2012 Pharma deals for April 2012

    In addition, following Biotie Therapies' decision last year not to complete its takeover of Newron Pharmaceuticals, Newron have now signed a collaboration and option agreement with Zambon for safinamide, which is ... 30. Newron Pharmaceuticals / Zambon (a

  • Oncology bias in pharma deals

    disease) to Newron Pharmaceuticals, triggered the termination of Biotie Therapeutics' acquisition of Newron. ... immunotherapy in phase III for non-small cell lung cancer. 7. Newron Pharmaceuticals/Biotie Therapeutics.

More from news
Approximately 2 fully matching, plus 4 partially matching documents found.

Latest appointments

  • Newron Pharma appoints commercial affairs VP Newron Pharma appoints commercial affairs VP

    Newron Pharma appoints commercial affairs VP. Dennis Dionne brings expertise from J&J and Novartis. ... Milan, Italy-based Newron Pharmaceuticals has promoted Dennis Dionne to vice president of commercial affairs.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Research Partnership

We are one of the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics